Fresenius Medical Care (FME) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
3 Feb, 2026Strategic sustainability focus areas
Sustainability is integrated into core operations, focusing on patient care, team development, and environmental impact.
Patient Net Promoter Score increased to 72, with 78% of patients highly recommending services, exceeding targets and industry standards.
Female leadership in top management levels rose to 34%, up from 30% the previous year.
Employees averaged over 38 hours of training, with over 143,000 participating in digital learning.
Supported more than 1,600 employees with nearly €1.7 million in grants through the FME CARES Fund.
Enhancing quality of care and access to healthcare
Provided care to over 332,000 patients across approximately 4,000 dialysis clinics.
Increased patient referrals to kidney transplantation clinics by 42% in the U.S. via the Referral Ready IT platform.
Shared insights through more than 170 published scientific research documents.
Climate action plan and emissions targets
Scope 1 and 2 emissions decreased by 16% compared to 2020, with a goal of 50% reduction by 2030 and climate neutrality by 2040.
Five virtual power purchase agreements (VPPAs) were signed, expected to cover up to 46% of global electricity consumption.
Energy efficiency workshops identified over 100 opportunities, with major sites like Utah expecting annual savings of 130,000 MWh and €1 million.
U.S. clinic network energy management aims to save 15 MWh per clinic, covering over 1,400 clinics.
Solar panels in Portugal will supply 20-30% of energy needs at half of clinics by year-end.
Latest events from Fresenius Medical Care
- 2025 saw robust growth and margin expansion, with 2026 focused on HDF rollout and stability.FME
Q4 2025 (Media)24 Feb 2026 - Record profitability, innovation, and capital returns position the group for industry-leading growth.FME
Investor presentation24 Feb 2026 - Record 2025 profitability and margin gains set a high base for a cautious 2026 outlook.FME
Q4 202524 Feb 2026 - Operating income and net income surged in Q2 2024, with 2024 guidance confirmed.FME
Q2 20242 Feb 2026 - High-volume HDF reduces mortality and improves outcomes, with a major US launch planned for 2025.FME
Expert Call20 Jan 2026 - Operating income margin and net income surged in Q3 2024, with improved leverage and cost savings.FME
Q3 202416 Jan 2026 - High-volume HDF rollout and strong financials drive growth, with 2026 as a key transition year.FME
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Streamlined operations and innovation position the company for strong growth in 2025.FME
43rd Annual J.P. Morgan Healthcare Conference10 Jan 2026 - 18% operating income growth, improved leverage, and strong 2025 outlook with further savings.FME
Q4 20247 Jan 2026